CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

US Open: Wall Street mixed after weak ISM data 🧭

15:33 1 August 2024
  • US100 and US500 indices open roughly flat
  • Small-cap companies lose after ISM data
  • Dollar erases early gains
  • 10-year bond yields below 4.0%

This week is full of important information for stock market investors. Investors have not yet fully analyzed yesterday's Fed decision and Jerome Powell's speech, and today, just after the start of the cash session, they received another data set, this time the ISM for manufacturing. The report turned out to be much weaker than expected, with all components along with the main indicator falling lower except for the price subindex, which is an even worse scenario. Prices, however, fell quite significantly, confirming lower inflationary pressure. Notably, the labor market is deteriorating. The employment subindex came in at 43.4 points versus an expected 49.0 and 49.3 previously. This is a very low reading. Given the mention of the dual mandate and labor market issues in yesterday's Fed statement, low ISM data and higher unemployment benefits increase the chances of rate cuts at the September meeting. However, after the data was released, the market saw more confusion than euphoria, as investors are now turning their attention to the potential for a recession. Much worse data may paradoxically increase sell-offs, contrary to what we have seen recently.

In the stock market, small-cap companies are faring the worst today. US2000 is down 1.60%. This is because small businesses will feel the effects of a slowing economy the most. US100 is also experiencing declines, but limited to -0.60% at the time of publication.

Start investing today or test a free demo

Open account Try demo Download mobile app Download mobile app

US500

The main US500 index is down 0.20%, the least among those mentioned above. Despite the mixed sentiment, we are currently seeing a rebound after a local low around 5440 points.

Source: xStation 5

Company news

Meta Platforms (META.US) gains 7% after reporting better-than-expected Q2 results, with operating income up by 58%. The company also noted a 7% increase in family daily active people, a 10% rise in ad impressions, and a 10% increase in the average price per ad. Meta projects Q3 sales between $38.5B and $41B, above the consensus of $39.2B, and raised its 2024 capex range to $37B-$40B.

Carvana (CVNA.US) jumped by over 12% following strong Q2 results. The company reported a profit of $0.14 per share, reversing a loss of $0.55 per share a year ago, and beating expectations for a loss of $0.12 per share. Total revenue increased by 15% to $3.41B, with adjusted EBITDA more than doubling to $355M. Carvana sold over 101K vehicles in the quarter, a 33% Y/Y increase, and expects adjusted EBITDA of $1.0B to $1.2B for FY24.

Teladoc Health (TDOC.US) dips 6% after the telehealth provider withdrew its 2024 financial guidance and three-year business outlook following mixed Q2 results. For 2024, the company projects revenue growth in the Integrated Care segment to be in the low to mid-single digits compared to 2023.

Arm Holdings (ARM.US) plunged by 11.70% despite exceeding FQ1 expectations. The company's midpoint outlook for FQ2, with adjusted earnings projected between $0.23 and $0.27 per share, fell short of market expectations, suggesting $0.25 compared to the consensus of $0.28. Revenue is expected to range from $780M to $830M.

Moderna (MRNA.US) declines by 14% after the company reduced its FY2024 outlook for product sales due to lower COVID vaccine sales. Despite exceeding Q2 expectations, total revenue declined 30% Y/Y, with net product sales dropping 73% to $184M. The company revised its net product sales guidance to $3B-$3.5B from around $4.5B.

Hershey (HSY.US dropped 2.0% after reporting Q2 results below expectations and issuing softer profit guidance. Q2 revenue fell 16.7% Y/Y with organic sales down 16.8%, including a 22% decline in the North America Confectionary segment. Adjusted gross margin decreased by 200 basis points, and adjusted operating profit plunged 32.8%. For FY24, Hershey expects revenue around $11.4B and EPS of $9.49 to $9.59.

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Back
Xtb logo

Join over 1 Million investors from around the world

We use cookies

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

This group contains cookies that are necessary for our websites to work. They take part in functionalities like language preferences, traffic distribution or keeping user session. They cannot be disabled.

Cookie name
Description
SERVERID
userBranchSymbol cc 2 March 2024
adobe_unique_id cc 1 March 2025
test_cookie cc 1 March 2024
SESSID cc 9 September 2022
__hssc cc 1 March 2024
__cf_bm cc 1 March 2024
intercom-id-iojaybix cc 26 November 2024
intercom-session-iojaybix cc 8 March 2024

We use tools that let us analyze the usage of our page. Such data lets us improve the user experience of our web service.

Cookie name
Description
_gid cc 9 September 2022
_gat_UA-22576382-1 cc 8 September 2022
_gat_UA-121192761-1 cc 8 September 2022
_ga_CBPL72L2EC cc 1 March 2026
_ga cc 1 March 2026
AnalyticsSyncHistory cc 8 October 2022
af_id cc 31 March 2025
afUserId cc 1 March 2026
af_id cc 1 March 2026
AF_SYNC cc 8 March 2024
__hstc cc 28 August 2024
__hssrc

This group of cookies is used to show you ads of topics that you are interested in. It also lets us monitor our marketing activities, it helps to measure the performance of our ads.

Cookie name
Description
MUID cc 26 March 2025
_omappvp cc 11 February 2035
_omappvs cc 1 March 2024
_uetsid cc 2 March 2024
_uetvid cc 26 March 2025
_fbp cc 30 May 2024
fr cc 7 December 2022
muc_ads cc 7 September 2024
lang
_ttp cc 26 March 2025
_tt_enable_cookie cc 26 March 2025
_ttp cc 26 March 2025
hubspotutk cc 28 August 2024

Cookies from this group store your preferences you gave while using the site, so that they will already be here when you visit the page after some time.

Cookie name
Description
personalization_id cc 7 September 2024
UserMatchHistory cc 8 October 2022
bcookie cc 8 September 2023
lidc cc 9 September 2022
lang
bscookie cc 8 September 2023
li_gc cc 7 March 2023

This page uses cookies. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. For more information see our Privacy Policy You can manage cookies by clicking "Settings". If you agree to our use of cookies, click "Accept all".

Change region and language
Country of residence
Language